ArticleClinical case reports2025
Zanubrutinib Combined With Rituximab in the Treatment of Bing-Neel Syndrome: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zanubrutinib Combined With Rituximab in the Treatment of Bing-Neel Syndrome: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bing-Neel syndrome (BNS) is a rare complication of Waldenström macroglobulinemia, a condition with low incidence in clinical practice and prone to misdiagnosis. Vigilance is crucial for identifying this condition in patients with Waldenström macroglobulinemia presenting with neurological symptoms. In cases where a pathological biopsy is inconclusive, cerebrospinal fluid flow cytometry can be utilized to aid in diagnosis. Currently, there is no established standard treatment protocol for BNS, and treatment outcomes vary. In this study, a combination of zanubrutinib and R-CHOP regimen was administered, with zanubrutinib being continued for the management of BNS, resulting in a notably favorable response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.